MyFinsight
Home
Blog
About
Cash and cash
equivalents
$50,774K
(62.77%↑ Y/Y)
Prepaid expenses and
other current assets
$785K
(-39.38%↓ Y/Y)
Other receivables
$25K
(-98.98%↓ Y/Y)
Total current assets
$51,584K
(-13.16%↓ Y/Y)
Operating lease right of
use assets
$1,029K
(-59.87%↓ Y/Y)
Other assets
$153K
(0.00%↑ Y/Y)
Total assets
$52,766K
(-15.06%↓ Y/Y)
Total liabilities and
stockholders' equity
$52,766K
(-15.06%↓ Y/Y)
Total stockholders'
equity
$44,204K
(34.65%↑ Y/Y)
Total liabilities
$8,562K
(-70.77%↓ Y/Y)
Accumulated deficit
-$467,821K
(1.55%↑ Y/Y)
Additional paid-in capital
$511,967K
(0.79%↑ Y/Y)
Total current
liabilities
$8,428K
(-43.61%↓ Y/Y)
Other long-term
liabilities
$91K
Non-current operating lease
liabilities
$43K
(-97.57%↓ Y/Y)
Common stock, 0.001 par
value 240,000,000...
$58K
(3.57%↑ Y/Y)
Accrued expenses and
other current...
$6,110K
(-9.17%↓ Y/Y)
Operating lease
liabilities
$2,000K
(8.46%↑ Y/Y)
Income taxes payable
$163K
(0.00%↑ Y/Y)
Accounts payable
$155K
(-80.13%↓ Y/Y)
Back
Back
Balance Sheet
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)
source: myfinsight.com